News, Articles & Media

NZ biotech firm makes giant strides in cancer fight

ComputerWorld New Zealand‘s Randal Jackson speaks with Caldera’s Graham Watt and Kristen Chalmet

health_care_2

13 May 2015– A privately owned New Zealand biotech company has made huge progress in developing a replacement for the PSA prostate cancer test.

At present, there are 100 million PSA tests conducted worldwide each year but the test reliability suffers from false negative and false positive results with PSA testing costing global health systems around US$2 billion annually.

Caldera Ltd was established in 2010 as a molecular diagnostic development company. Prostate cancer is its first target, though the current development work has the potential, eventually, to target all cancers.

Breast cancer would be be the next target, says managing director Graham Watt.

Read the full Computerworld New Zealand article here